COMPASS Pathways Plc (CMPS)

American Depository Receipt

Sell: $5.27|Buy: $5.56|Change: 0.29 (5.53%)

Open

$5.35

Previous close

$5.24

Trade high

$5.64

Volume

1,988,982

Year high

$8.90

Year low

$2.25

Dividend yield

–

Market capitalisation

$627.75 mn

P/E ratio

–

ISIN

US20451W1018

This share can be held in a Dealing account SIPP

Share price

Performance 31/03/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
COMPASS Pathways Plc	+ 5.53
More...

Company profile

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.